Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia

被引：32

作者：

Sandhu, Karamjeet S. ^{[1
]}

Dadwal, Sanjeet ^{[1
]}

Yang, Dongyun ^{[1
]}

Mei, Matthew ^{[1
]}

Palmer, Joycelynne ^{[1
]}

Salhotra, Amandeep ^{[1
]}

Al Malki, Monzr ^{[1
]}

Aribi, Ahmed ^{[1
]}

Ali, Haris ^{[1
]}

Khaled, Samer ^{[1
]}

Forman, Stephen J. ^{[1
]}

Snyder, David ^{[1
]}

Nakamura, Ryotaro ^{[1
]}

Stein, Anthony S. ^{[1
]}

Marcucci, Guido ^{[1
]}

Aldoss, Ibrahim ^{[1
]}

Pullarkat, Vinod ^{[1
]}

机构：

[1] City Hope Med Ctr, Gehr Family Ctr Leukemia Res, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2020年 / 26卷 / 12期

关键词：

Acute myelogenous leukemia; Hypomethylating agents; Venetoclax; Allogeneic hematopoietic cell transplantation; ACUTE MYELOID-LEUKEMIA; FUNGAL-INFECTIONS; DISEASE; MARROW; GRAFT;

D O I：

10.1016/j.bbmt.2020.08.027

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The combination of hypomethylating agents with the selective Bcl-2 inhibitor venetoclax (HMA-VEN) has emerged as a highly active regimen in patients with acute myelogenous leukemia (AML) in both the upfront and relapsed/refractory (r/r) settings. We report our early experience with a cohort of patients who were able to proceed to allogeneic hematopoietic cell transplantation (alloHCT) after HMA-VEN therapy. Thirty-two patients with AML (19 r/r and 13 de novo) with a median age of 62 years underwent alloHCT after HMA-VEN therapy. Twentytwo (68.8%) were in complete remission (CR)/CR with incomplete count recovery at time of HCT. With a median follow up of 14.4 months, the 1-year overall survival (OS) was 62.5%, and disease-free survival was 43.8%. The 1 year nonrelapse mortality rate was 18.8%, and the cumulative incidence of relapse was 37.5%. Among patients who underwent alloHCT in CR, the 1-year OS was 77.3%, and the cumulative incidence of nonrelapse mortality was 9.1%. The cumulative incidence of grade II-IV acute graft-versus-host disease was 43.8%. We conclude that alloHCT after HMA-VEN is therapy associated with favorable allogeneic HCT outcomes in newly diagnosed older patients with AML, as well as those with r/r AML. (C) 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

引用

页码：E322 / E327

页数：6

共 19 条

[1] Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents [J].

Aldoss, Ibrahim ;

Dadwal, Sanjeet ;

Zhang, Jianying ;

Tegtmeier, Bernard ;

Mei, Matthew ;

Arslan, Shukaib ;

Al Malki, Monzr M. ;

Salhotra, Amandeep ;

Ali, Haris ;

Aribi, Ahmed ;

Sandhu, Karamjeet ;

Khaled, Samer ;

Snyder, David ;

Nakamura, Ryotaro ;

Stein, Anthony S. ;

Forman, Stephen J. ;

Marcucci, Guido ;

Pullarkat, Vinod .

BLOOD ADVANCES, 2019, 3 (23) :4043-4049

[2] Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia [J].

Aldoss, Ibrahim ;

Zhang, Jianying ;

Pillai, Raju ;

Shouse, Geoffrey ;

Sanchez, James F. ;

Mei, Matthew ;

Nakamura, Ryotaro ;

Stein, Anthony S. ;

Forman, Stephen J. ;

Marcucci, Guido ;

Pullarkat, Vinod .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (02) :E45-E48

[3] Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia [J].

Aldoss, Ibrahim ;

Yang, Dongyun ;

Pillai, Raju ;

Sanchez, James F. ;

Mei, Matthew ;

Aribi, Ahmed ;

Ali, Haris ;

Sandhu, Karamjeet ;

Al Malki, Monzr M. ;

Salhotra, Amandeep ;

Khaled, Samer ;

Sun, Weili ;

O'Donnell, Margaret ;

Snyder, David ;

Nakamura, Ryotaro ;

Stein, Anthony S. ;

Forman, Stephen J. ;

Marcucci, Guido ;

Pullarkat, Vinod .

AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (10) :E253-E255

[4] Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia [J].

Aldoss, Ibrahim ;

Yang, Dongyun ;

Aribi, Ahmed ;

Ali, Haris ;

Sandhu, Karamjeet ;

Al Malki, Monzr M. ;

Mei, Matthew ;

Salhotra, Amandeep ;

Khaled, Samer ;

Nakamura, Ryotaro ;

Snyder, David ;

O'Donnell, Margaret ;

Stein, Anthony S. ;

Forman, Stephen J. ;

Marcucci, Guido ;

Pullarkat, Vinod .

HAEMATOLOGICA, 2018, 103 (09) :E404-E407

[5] Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].

De Pauw, Ben ;

Walsh, Thomas J. ;

Donnelly, J. Peter ;

Stevens, David A. ;

Edwards, John E. ;

Calandra, Thierry ;

Pappas, Peter G. ;

Maertens, Johan ;

Lortholary, Olivier ;

Kauffman, Carol A. ;

Denning, David W. ;

Patterson, Thomas F. ;

Maschmeyer, Georg ;

Bille, Jacques ;

Dismukes, William E. ;

Herbrecht, Raoul ;

Hope, William W. ;

Kibbler, Christopher C. ;

Kullberg, Bart Jan ;

Marr, Kieren A. ;

Munoz, Patricia ;

Odds, Frank C. ;

Perfect, John R. ;

Restrepo, Angela ;

Ruhnke, Markus ;

Segal, Brahm H. ;

Sobel, Jack D. ;

Sorrell, Tania C. ;

Viscoli, Claudio ;

Wingard, John R. ;

Zaoutis, Theoklis ;

Bennett, John E. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821

[6] Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia [J].

DiNardo, Courtney D. ;

Pratz, Keith ;

Pullarkat, Vinod ;

Jonas, Brian A. ;

Arellano, Martha ;

Becker, Pamela S. ;

Frankfurt, Olga ;

Konopleva, Marina ;

Wei, Andrew H. ;

Kantarjian, Hagop M. ;

Xu, Tu ;

Hong, Wan-Jen ;

Chyla, Brenda ;

Potluri, Jalaja ;

Pollyea, Daniel A. ;

Letai, Anthony .

BLOOD, 2019, 133 (01) :7-17

[7] Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies [J].

DiNardo, Courtney D. ;

Rausch, Caitlin R. ;

Benton, Christopher ;

Kadia, Tapan ;

Jain, Nitin ;

Pemmaraju, Naveen ;

Daver, Naval ;

Covert, Wendy ;

Marx, Kayleigh R. ;

Mace, Morgan ;

Jabbour, Elias ;

Cortes, Jorge ;

Garcia-Manero, Guillermo ;

Ravandi, Farhad ;

Bhalla, Kapil N. ;

Kantarjian, Hagop ;

Konopleva, Marina .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (03) :401-407

[8] Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet [J].

Doehner, Hartmut ;

Estey, Elihu H. ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Burnett, Alan K. ;

Dombret, Herve ;

Fenaux, Pierre ;

Grimwade, David ;

Larson, Richard A. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel A. ;

Sierra, Jorge ;

Tallman, Martin S. ;

Loewenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2010, 115 (03) :453-474

[9] A proportional hazards model for the subdistribution of a competing risk [J].

Fine, JP ;

Gray, RJ .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509

[10] Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation [J].

Gilleece, Maria H. ;

Labopin, Myriam ;

Yakoub-Agha, Ibrahim ;

Volin, Liisa ;

Socie, Gerard ;

Ljungman, Per ;

Huynh, Anne ;

Deconinck, Eric ;

Wu, Depei ;

Bourhis, Jean Henri ;

Cahn, Jean Yves ;

Polge, Emmanuelle ;

Mohty, Mohamad ;

Savani, Bipin N. ;

Nagler, Arnon .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (09) :1142-1152

← 1 2 →